ArticleResearch (Washington, D.C.)2025
ZDHHC14-Mediated TEAD4 Palmitoylation Drives Th17 Cell Recruitment in Renal Immunopathology.
Article in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Metabolic Reprogramming and Immunometabolic Dysregulation in Diabetic Kidney Disease: From Pathogenesis to Precision Multi-target Therapies.Research (Washington, D.C.) · 2026Review
- Lymphatic-Immune Microenvironment Engineering via Rapamycin-Eluting Nanofibers for Meningeal Repair and Neuroprotection in Traumatic Brain Injury Rats.Research (Washington, D.C.) · 2026Article
- Post-translational protein S-palmitoylation in renal tubular injury: mechanisms and therapeutic implications.Frontiers in cell and developmental biology · 2026Review
- Scoparone-Induced Phase Separation of ZDHHC12 Drives Ferroptosis via ATG12 S-palmitoylation and Ferritinophagy in Liver Fibrosis.Research (Washington, D.C.) · 2026Article
- The Roles of ProteinCancer communications (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Palmitoylation, a crucial posttranslational protein modification, plays an undefined role in immune-mediated kidney diseases. This study reveals a novel mechanism whereby palmitoylation regulates the activity of transcription factor TEAD4 to facilitate T helper 17 (Th17) cell recruitment in IgA nephropathy (IgAN), suggesting that inhibition of palmitoylation could serve as a "brake" mechanism to impede disease progression. By analyzing samples from IgAN patients and mouse models, we identified a marked positive correlation between the extent of Th17 cell infiltration in renal tissues and disease severity. Mechanistically, under inflammatory conditions, injured tubular epithelial cells up-regulate CCL20 expression through the transcription factor TEAD4, thereby facilitating Th17 cell recruitment. Notably, TEAD4 activity is regulated by palmitoylation modification rather than changes in protein expression levels. Further analysis identified ZDHHC14 as the key palmitoyltransferase mediating TEAD4 palmitoylation, which is highly expressed in renal tissues of both IgAN patients and model mice. Knockdown of ZDHHC14 effectively reduced CCL20 expression and subsequent Th17 cell infiltration. In vivo therapeutic experiments demonstrated that administration of the ZDHHC inhibitor 2-BP effectively attenuated Th17 cell infiltration and renal interstitial fibrosis in model mice, markedly delaying disease progression. This study provides the first evidence of TEAD4 palmitoylation-mediated regulation in immune-mediated kidney and proposes a novel strategy to modulate Th17-driven disorders, with broad implications for autoimmune and fibrotic diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.